摘要
为规范眩晕症的科学用药,中国医药教育协会眩晕专业委员会特成立专家小组,在纳入现有医学科学证据的基础上,结合专家丰富的临床经验,经反复讨论后形成《甲磺酸倍他司汀治疗眩晕症的专家共识》。本共识包括组胺类药物的药理基础以及甲磺酸倍他司汀在常见眩晕疾病(如良性阵发性位置性眩晕、梅尼埃病、前庭神经炎等)中的用药推荐等级、剂量、疗程、复查方法、特殊人群用药、药物不良反应等方面,旨在帮助医生提升临床实践水平。
In order to standardize scientific drug use in vertigo,the Vertigo Committee of the Chinese Medical Education Association established an expert group to form Expert Consensus on Betahistine Mesylate in the Treatment of Vertigo after repeated discussion based on the existing medical evidence,and combined with the rich clinical experience of experts.The consensus includes the pharmacological basis of histamines,the strength of recommendation,dosage,course,review methods,medication for special populations,adverse drug reactions and other aspects of betahistine mesylate in common vertigo diseases(such as benign paroxysmal position vertigo,Menieres disease,and vestibular neuritis,etc.)to guide doctors in clinical work.
出处
《中国全科医学》
北大核心
2023年第29期3591-3598,共8页
Chinese General Practice
关键词
眩晕
良性阵发性位置性眩晕
梅尼埃病
前庭神经元炎
倍他司汀
临床用药
Vertigo
Benign paroxysmal positional vertigo
Meniere disease
Vestibular neuronitis
Betahistine
Clinical medication
